Skip to main content

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 3 points (0.0%) at 17,053 as of Friday, Oct. 9, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,606 issues advancing vs. 1,356 declining with 155 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is up 1.7%. On the negative front, top decliners within the sector include

Alexion Pharmaceuticals

(

ALXN

), down 2.3%,

Celgene

(

CELG

), down 1.5%,

Shire

(

TheStreet Recommends

SHPG

), down 1.3%,

Novartis

(

NVS

), down 1.1% and

Bristol-Myers Squibb Company

(

BMY

), down 1.1%. Top gainers within the sector include

Centene

(

CNC

), up 3.6%,

Medivation

(

MDVN

), up 3.5%,

Anthem

(

ANTM

), up 2.2%,

Eli Lilly and

(

LLY

), up 2.0% and

Valeant Pharmaceuticals International

(

VRX

), up 1.8%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

LDR

(

LDRH

) is one of the companies pushing the Health Care sector lower today. As of noon trading, LDR is down $9.68 (-26.7%) to $26.53 on heavy volume. Thus far, 3.6 million shares of LDR exchanged hands as compared to its average daily volume of 280,500 shares. The stock has ranged in price between $26.52-$28.48 after having opened the day at $27.64 as compared to the previous trading day's close of $36.21.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

LDR Holding Corporation, a medical device company, focuses on designing and commercializing various surgical technologies for the treatment of patients suffering from spine disorders in the United States and internationally. LDR has a market cap of $987.6 million and is part of the health services industry. Shares are up 10.5% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts that rate LDR a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates

LDR

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow and feeble growth in its earnings per share. Get the full

LDR Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mallinckrodt

(

MNK

) is down $2.10 (-3.1%) to $66.44 on average volume. Thus far, 1.1 million shares of Mallinckrodt exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $66.29-$69.18 after having opened the day at $69.00 as compared to the previous trading day's close of $68.54.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging. Mallinckrodt has a market cap of $7.7 billion and is part of the drugs industry. Shares are down 30.8% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Mallinckrodt a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Mallinckrodt

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, a generally disappointing performance in the stock itself and generally higher debt management risk. Get the full

Mallinckrodt Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Teva Pharmaceutical Industries

(

TEVA

) is down $0.53 (-0.9%) to $58.71 on light volume. Thus far, 1.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $58.69-$60.31 after having opened the day at $60.05 as compared to the previous trading day's close of $59.24.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. Teva Pharmaceutical Industries has a market cap of $49.1 billion and is part of the drugs industry. Shares are up 3.0% year-to-date as of the close of trading on Thursday. Currently there are 12 analysts that rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Teva Pharmaceutical Industries

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Teva Pharmaceutical Industries Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).